Abstract
The SYMPHONY study established low dose tacrolimus, mycophenolate, prednisolone and IL-2 receptor antagonist induction, as standard of care for immunosuppression in kidney transplant recipients (KTRs). In our service, we reduced the starting tacrolimus dose from 0.075mg/kg BD (higher dose (HD)) to 0.05mg/kg BD (lower dose (LD)) to minimise supratherapeutic tacrolimus levels in the early post-transplant period. The aim of our study was to compare the LD and HD starting tacrolimus regimens in KTRs with respect to achieved tacrolimus levels and clinical outcomes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
